Costs and benefits of improving renal failure treatment - Where do we go?

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2049-2052

  Jacobs, Claude ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chronic kidney disease; Dialysis; Economics; Nephroprotection

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DIABETIC NEPHROPATHY; DISEASE COURSE; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PROMOTION; HEMODIALYSIS; HIGH RISK POPULATION; HOME DIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE; MEDICAL EDUCATION; META ANALYSIS; MORBIDITY; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RENAL PROTECTION; SOCIAL ASPECT; SURVIVAL TIME; TREATMENT PLANNING;

COMORBIDITY; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; FORECASTING; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY;

EID: 33748064645     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl168     Document Type: Note

References (39)

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005; 20: 2587-2593
2. Lameire N, Jager K, Van Biesen W, De Bacquer D, Vanholder R. Chronic kidney disease: A European perspective. Nephrol Dial Transplant 2005; 68 [Suppl 99]: S30-S38
3. Schmieder RE. Nephroprotection by antihypertensive agents. J Cardiovasc Pharmacol 1994; 24 [Suppl 2]: S55-S64
4. El Nahas AM, Bello AK. Chronic kidney disease: The global challenge. Lancet 2005; 365: 331-340
5. Coresh J, Bird-Holt D, Astor BC et al. Chronic kidney disease awareness, prevalence and trends among U.S. adults 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-188
6. US Renal Data System. Annual data report 2005 (http://www.usrds.org)
7. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
8. Dirks JH, De Zeeuw D, Sanjay K et al. Prevention of chronic kidney and vascular disease: Toward global health equity. The Bellagio 2004 declaration. Kidney Int 2005; 68 [Suppl 98]: S1-S6
9. International Society of Nephrology. 2004 consensus workshop on prevention of progression of renal disease. Kidney Int 2005; 67[Suppl 94]: S2-S7
10. De Francisco ALM, Fernandez Fresnedo G, Palomar R, Pinera C, Arias M. The renal benefit of a healthy lifestyle. Kidney Int 2005; 68 [Suppl 99]: S2-S6
11. Giatras I, Lau J, Levey AS. Effect of an angiotensin-converting enzyme inhibitor on the progression of non-diabetic renal disease: A meta-analysis of randomized trials. Ann Int Med 1997; 127: 337-345
12. Jafar H, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Ann Int Med 2001; 135: 73-87
13. Kasiske BL, Kalik RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes; a meta-regression analysis. Ann Int Med 1993; 118: 124-138
14. Weidmann P, Schneider M, Böhlen L. Therapeutic effect of different antihypertensive drugs in human diabetic nephropathy: An updated meta analysis. Nephrol Dial Transplant 1995; 10 [Suppl 9]: 39-45
15. ACE-inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Ann Int Med 2001; 134: 370-379
16. Lowell HG. Angiotensin-converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria (Cochrane Review). The Cochrane Library, Issue 3, John Wiley & Sons, Chichester: 2004
17. Gansevoort RT, Sluiter WJ, Hemmelder MH, De Zeeuw D, De Jong PE. Anti proteinuric effect of blood pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-1974
18. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Int Med 1995; 155: 1073-1080
19. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE-inhibitors in diabetic and non-diabetic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35: 695-707
20. Anaes-Haute Autorité de santé. Moyens thérapeutiques pour ralentir la progression de l'insuffisance rénale chronique chez l'adulte. http://www.anaes.fr/HAS/Publications
21. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin-converting inhibition on diabetic nephropathy. N Engl J Med 1993; 399: 1456-1462
22. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
23. Remuzzi G, Ruggenenti P, Perna A et al. Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post-hoc analysis of the RENAAL Trial results. J Am Soc Nephrol 2004; 15: 117-125
24. Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 67 [Suppl 92]: S115-S117
25. Rippin JD, Barnett AH, Bain SC. Cost effective strategies in the prevention of diabetic nephropathy. Pharmacoeconomics 2004; 22: 9-28
26. Friedman EA. Facing the reality: The world cannot afford uremia therapy at the start of the 21st. century. Artif Organs 1995; 19: 481-485
27. De Vecchi AF, Dratwa M, Wiedemann ME. Systems and end-stage renal disease therapies. An international review: Costs and reimbursement/ funding of ESRD therapies. Nephrol Dial Transplant 1999; 14 [Suppl 6]: 31-41
28. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 53: 53-58
29. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005; 16: 1859-1865
30. Mowatt G, Vale S, Perez J et al. Systemic review of the effectiveness and cost-effectiveness and economic evaluation of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess 2003; 7: 1-174
31. Lee H, Manns B, Taub K, Hali WA, Dean S, Johnson D, Donaldson C. Cost analysis of on-going care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 2002; 40: 611-622
32. Kutner NG, Zhang R, Barnhardt DT, Collins AJ. Health status and quality of life reported by incident patients after one year on haemodialysis or peritoneal dialysis. Nephrol Dial Transplant 2005; 20: 2159-2167
33. Shih YCT, Guo A, Just PM, Mujais S. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int 2005; 68: 319-329
34. Thanamayooran S, Rose C, Hirsch DJ. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guidelines targets. Nephrol Dial Transplant 2005; 20: 2385-2393
35. Levin A. The need for optimal and coordinated management of CKD. Kidney Int 2005; 68 [Suppl 99]: S7-S10
36. Jungers P, Choukroun G, Robino C et al. Epidemiology of end-stage renal disease in the Ile- de France area: A prospective study in 1998. Nephrol Dial Transplant 2000; 15: 2000-2006
37. Huisman RM. The deadly risk of late referral. Nephrol Dial Transplant 2004; 19: 2175-2180
38. Wauters JP, Lameire N, Davison A, Ritz E. Why patients with progressing kidney disease are referred too late to the nephrologists: On causes and proposals for improvement. Nephrol Dial Transplant 2005; 20: 490-496
39. Goovaerts T, Jadoul M, Goffin E. Influence of a pre-dialysis education programme on the mode of renal replacement therapy. Nephrol Dial Transplant 2005; 20: 1842-1847